Saul H. Rosenberg
AbbVie (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Cancer therapeutics and mechanisms, Multiple Myeloma Research and Treatments, Cell death mechanisms and regulation, DNA Repair Mechanisms
Most-Cited Works
- → An inhibitor of Bcl-2 family proteins induces regression of solid tumours(2005)3,369 cited
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor(2008)1,942 cited
- → Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity(2010)845 cited
- → The promise and peril of chemical probes(2015)841 cited
- → Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours(2017)825 cited
- →